Contrive Datum Insights_Logo.jpg
The Automated Guided Vehicles Market is projected to grow from USD 2.17 billion in 2022 to USD 4.11 billion by 2030, exhibiting a CAGR of 9.6% during the forecast period.| Data By Contrive Datum Insights Pvt Ltd.
May 11, 2023 17:00 ET | Contrive Datum Insights Pvt Ltd
Farmington, May 11, 2023 (GLOBE NEWSWIRE) -- The Global Automated Guided Vehicles Market is projected to grow from USD 2.17 billion in 2022 to USD 4.11 billion by 2030, exhibiting a CAGR of 9.6%...
AI_envisioned_cmyk.png
Ambarella Announces First Quarter Fiscal Year 2024 Earnings Conference Call to be Held May 30, 2023
May 09, 2023 05:00 ET | Ambarella
SANTA CLARA, Calif., May 09, 2023 (GLOBE NEWSWIRE) -- Ambarella, Inc. (NASDAQ: AMBA), an edge AI semiconductor company, today announced it will hold its first quarter fiscal year 2024 earnings...
endogena_logo.png
Endogena Therapeutics Completes Enrollment Ahead of Schedule in its Phase 1/2a Trial of EA-2353 for Retinitis Pigmentosa
May 04, 2023 03:00 ET | Endogena
SAN FRANCISCO and TORONTO and ZÜRICH, Switzerland, May 04, 2023 (GLOBE NEWSWIRE) -- Endogena Therapeutics Inc., a clinical-stage biotech company, is pleased to announce that it has completed...
ONL logo.jpg
ONL Therapeutics Announces First Patient Dosed in Phase 2 Clinical Trial of First-in-Class Fas-Inhibitor in Patients with Macula-Off Rhegmatogenous Retinal Detachment
April 12, 2023 07:00 ET | ONL Therapeutics
ANN ARBOR, Mich., April 12, 2023 (GLOBE NEWSWIRE) -- ONL Therapeutics, Inc., a clinical-stage biopharmaceutical company developing novel therapies for protecting the vision of patients with retinal...
ONL logo.jpg
ONL Therapeutics to Report Clinical Data on ONL1204 in Podium Presentation at the Association for Research in Vision and Ophthalmology (ARVO) Annual Meeting
April 11, 2023 07:00 ET | ONL Therapeutics
Presentation will review the results of ONL’s Phase 1 study of ONL1204 Ophthalmic Solution in patients with Macula-Off Rhegmatogenous Retinal Detachment Preclinical data in models of inherited...
MaximizeMarketResearch
Vision Correction Market to reach USD 42.7 Mn by 2029 at a CAGR of 8.9 percent – says Maximize Market Research
April 10, 2023 07:36 ET | MAXIMIZE MARKET RESEARCH PRIVATE LIMITED
Pune, April 10, 2023 (GLOBE NEWSWIRE) -- A global Healthcare business consulting and research firm, Maximize Market Research, has published a market intelligence and competitive landscape report on...
ONL logo.jpg
ONL Therapeutics Closes First Tranche of $15 Million Series C Financing to Advance Lead Compound into Phase 2 Clinical Trial
March 08, 2023 07:00 ET | ONL Therapeutics
ANN ARBOR, Mich., March 08, 2023 (GLOBE NEWSWIRE) -- ONL Therapeutics, Inc., a clinical-stage biopharmaceutical company developing novel therapies for protecting the vision of patients with retinal...
NTTSNew
New to The Street Announces TV Guests Appearances on Episodes 444 and 445 that Start Airing on Saturday, March 4, 2023, at 3:30 PM ET
March 03, 2023 09:30 ET | FMW Media Works Corp
NEW YORK, March 03, 2023 (GLOBE NEWSWIRE) -- FMW Media's New to The Street announces its corporate guests appearances on episodes 444 and 445, airing as a syndicated televised platform on Newsmax TV...
July 30, 2021 - ROSEN LOGO.jpg
ROSEN, A LEADING INVESTOR RIGHTS LAW FIRM, Encourages International Business Machines Corporation Investors to Secure Counsel Before Important Deadline in Securities Class Action Initiated by the Firm – IBM
March 01, 2023 14:22 ET | The Rosen Law Firm PA
NEW YORK, March 01, 2023 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of International Business Machines Corporation (NYSE: IBM)...
ONL logo.jpg
ONL Therapeutics to Present at the XXVth Biennial Meeting of the International Society for Eye Research
February 13, 2023 07:00 ET | ONL Therapeutics
ANN ARBOR, Mich., Feb. 13, 2023 (GLOBE NEWSWIRE) -- ONL Therapeutics, Inc., a clinical-stage biopharmaceutical company developing novel therapies for protecting the vision of patients with retinal...